

November 15, 2024

Third Quarter Update—Management Guides to Profitability in 2025 Driven by HOPE Therapeutics

In Q3 2024, NRx Pharmaceuticals reduced its operating net loss by nearly 75% year-over-year to \$1.6 million, driven by significant reductions in R&D expenses due to the conclusion of a Phase 2b/3 study for NRX-101. For the nine months ended September 30, 2024, net loss improved by \$9.7 million to \$16.1 million, reflecting a 53% decrease in R&D costs and an 11% reduction in G&A expenses. The company held \$1.6 million in cash at quarter-end and secured \$5.4 million in financing post-quarter to support NDA filings, corporate purposes, and debt refinancing.

NDA's Ahead: NRx Pharmaceuticals is on track to file NDAs for NRX-100 (IV Ketamine) and NRX-101 by the end of 2024, aiming for a 2025 PDUFA date. Backed by extensive clinical data, NRX-100 has demonstrated significant reductions in suicidal ideation and could become the first approved treatment for acute suicidality. NRX-101 targets bipolar depression with suicidality or akathisia, addressing a multi-billion-dollar market with promising results from the Phase 2b/3 and STABIL-B trials.

HOPE IS REAL. Through its HOPE Therapeutics subsidiary, NRx is expanding a network of interventional psychiatry clinics focused on treating suicidal depression and PTSD, with plans to spin off the subsidiary as a separate entity. These revenue-generating, EBITDA-positive clinics are expected to contribute to first revenues by the end of 2024 and support the company's forecasted profitability in 2025. Recent funding of \$10.8 million will further support NDA filings and operational growth while retiring debt under favorable terms.

Key milestones: This year they include NDA filings for NRX-100 to treat suicidal ideation in depression and NRX-101 for bipolar depression with suicidality or akathisia, leveraging Breakthrough Therapy Designation and Priority Review. HOPE Therapeutics will continue building its clinic network, providing a foundation for future growth. These efforts position NRx to address critical unmet needs in mental health and suicide prevention while delivering shareholder value.

Valuation: Our \$31.00 price target is based on the success of NRX-100 and NRX-101, including revenues from the clinic acquisitions (Hope Therapeutics). Our valuation models include Free Cash Flow to the Firm (FCFF), discounted EPS (dEPS), and Sum-of-the-Parts (SOP). We use a 30% discount rate. This is in addition to our revenue models' 30% risk cut or 70% Probability of Success POS factor. We select 30% for micro-capitalized growth companies, representing our highest risk rate. These three models' results are equal-weighted, averaged, and rounded to the nearest whole number to provide a 12-month target price.

Risks to our thesis include: 1. Regulatory Approvals; 2—clinical Science; 3. Intellectual Capital; and 4. Dilution

Jason Kolbert

jkolbert@dboralcapital.com

MARKET DATA

Rating	Buy
Price Target	\$31.00
Price	\$1.16
Average Daily Volume (000)	115
52-Week Range (\$)	\$1.10–\$7.33
Market Cap (M)	\$12
Enterprise Value (M)	\$18
Book Value	(1.42)
Dividend Yield	0.0%
Cash (M)	\$2
Qrtly Burn Rate (M)	\$(2)

ESTIMATES

	2023A	2024E	2025E
Revenue (M)	\$0.0	\$0.0	\$107.2
Total Expenses ^{prev:} (M)	\$28	\$22	\$15
GAAP	\$(0.28)	\$(1.86)	\$1.02
EPS ^{prev:}	-	\$(2.11)	\$1.00

One Year Performance Chart



Please see analyst certification and important disclosures on page 3 of this report.

NRx Pharmaceuticals: Income Statement																
000 : YE December 31	2023A	1Q24A	2Q24A	3Q24A	4Q24E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
Product sales	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NRX-101 for BPD - Akathisia	-	-	-	-	-	-	70,311	105,467	210,933	351,556	1,054,667	1,230,445	1,265,601	1,265,601	1,265,601	1,335,912
NRX-100 (IV Ketamine)	-	-	-	-	-	-	9,707	38,415	251,449	625,350	1,038,634	1,151,314	1,416,339	1,416,339	1,416,339	1,416,339
PTSD / Pain	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Product Sales	-	-	-	-	-	-	80,018	143,882	462,383	976,906	2,093,302	2,381,759	2,681,939	2,681,939	2,681,939	2,752,250
Clinic-Psyc Center Revenues Net to Parent	-	-	-	-	-	-	17,500	36,400	56,238	77,234	98,473	120,531	139,347	149,019	149,019	158,871
Total Revenues	-	-	-	-	-	-	107,225	180,282	518,621	1,054,139	2,191,774	2,502,290	2,821,286	2,830,959	2,830,959	2,911,122
Expenses																
Product COGS	-	-	-	-	-	-	-	34,532	92,477	175,843	313,995	357,264	402,291	375,472	268,194	275,225
COGS %	-	-	-	-	-	-	-	24%	20%	18%	15%	15%	15%	14%	10%	10%
Research and Development	13,371	1,748	2,804	611	2,500	7,663	12,000	12,500	15,000	18,000	19,800	27,720	38,808	58,600	64,460	70,906
General and Administrative	14,216	4,250	4,246	2,411	3,900	14,807	14,955	15,105	15,256	19,070	22,884	26,316	27,632	27,908	28,187	28,469
Total Operating Expenses	27,837	5,998	7,050	3,022	6,400	22,470	14,955	49,636	107,732	194,913	336,879	383,580	429,923	403,380	296,381	303,694
Loss from Operations	(27,837)	(5,998)	(7,050)	(3,022)	(6,400)	(22,470)	65,063	94,246	354,651	781,993	1,756,423	1,998,179	2,252,017	2,278,560	2,385,558	2,448,556
Other (income) Expenses																
Gain on extinguishment of debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income	(494)	(27)	(7)	(6)	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense - Convertible note	120	230	849	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liability	2,707	318	23	(1,355)	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of Earnout Cash liability	(20)	9	(18)	(38)	-	-	-	-	-	-	-	-	-	-	-	-
Total other (income) expense	530	847	(1,399)	(1,399)	(1,399)	(1,399)	(1,399)	(1,399)	(1,399)	(1,399)	(1,399)	(1,399)	(1,399)	(1,399)	(1,399)	(1,399)
Net Loss	(30,150)	(6,528)	(7,897)	(1,623)	(6,400)	(22,470)	65,063	94,246	354,651	781,993	1,756,423	1,998,179	2,252,017	2,278,560	2,385,558	2,448,556
Deemed Dividend (& other)	(3)	-	-	-	-	-	-	4,712	28,372	78,199	316,156	479,563	630,565	683,568	739,523	808,024
Tax Rate	0%	0%	0%	0%	0%	0%	0%	5%	8%	10%	18%	24%	28%	30%	31%	33%
GAAP Net Income (loss)	(30,147)	(6,528)	(7,897)	(1,626)	(6,400)	(22,451)	65,063	89,533	326,279	703,794	1,440,267	1,518,616	1,621,452	1,594,992	1,646,035	1,640,533
GAAP-EPS	(0.40)	(0.74)	(0.75)	(0.15)	(0.36)	(1.99)	(0.43)	1.81	6.57	14.12	28.77	30.22	32.14	31.48	32.41	32.22
GAAP EPS (dil)	(0.28)	(0.74)	(0.75)	(0.15)	(0.36)	(1.86)	1.02	1.12	4.06	8.71	17.76	18.65	32.14	31.48	32.41	32.22
Wgtd Avg Shrs (Bas) '000	75,762	8,852	10,517	10,973	18,000	12,086	41,180	49,457	49,655	49,854	50,054	50,255	50,456	50,658	50,785	50,912
Wgtd Avg Shrs (Dil) '000	109,406	8,852	10,517	10,973	18,000	12,086	63,906	80,137	80,458	80,780	81,104	81,429	81,755	82,082	82,288	82,494

Source: Company reports and EF Hutton

Important Disclosures

Analyst Certification

I, Jason Kolbert, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.

Company-Specific Disclosures

D. Boral Capital, managed or co-managed a public offering of securities for NRx Pharmaceuticals, Inc. during the past 12 months.

D. Boral Capital, or its affiliates have received compensation from NRx Pharmaceuticals, Inc. for investment banking services within the past 12 months.

D. Boral Capital, or its affiliates will seek compensation from NRx Pharmaceuticals, Inc. for investment banking services within three months following publication of this research report.

General Disclosures

This report has been produced by D. Boral Capital LLC and is for informational purposes only. It does not constitute solicitation of the sale or purchase of securities or other investments. The information contained herein is derived from sources that are believed to be reliable. Prices, numbers, and similar data contained herein include past results, estimates, and forecasts, all of which may differ from actual data. These prices, numbers, and similar data may also change without prior notification. This research report does not guarantee future performance, and the information contained herein should be used solely at the discretion and responsibility of the client. Neither D. Boral Capital nor its affiliates accept any liability or responsibility for any results in connection with the use of such information. This research report does not consider specific financial situations, needs, or investment objectives of any client, and it is not intended to provide tax, legal, or investment advice. Clients are responsible for making final investment decisions and should do so after a careful examination of all documentation delivered prior to execution, explanatory documents pertaining to listed securities, etc., prospectuses, and other relevant documents. D. Boral Capital and its affiliates may make investment decisions based on this research report. In addition, D. Boral Capital and its affiliates, as well as employees, may trade in the securities mentioned in this research report, their derivatives, or other securities issued by the same issuing companies in this research report. This research report is distributed by D. Boral Capital and/or its affiliates. The information contained herein is for client use only.

D. Boral Capital holds the copyright on this research report. Any unauthorized use or transmission of any part of this research report for any reason, whether by digital, mechanical, or any other means, is prohibited. If you have any questions, please contact your sales representative. Additional information is available upon request.

Certain company names, product and/or service names that appear in this research report are trademarks or registered trademarks of D. Boral Capital or other companies mentioned in the report.

Copyright 2024 D. Boral Capital LLC.

D. Boral Capital rating definitions are expressed as the total return relative to the expected performance of S&P 500 over a 12-month period.

BUY (B) - Total return expected to exceed S&P 500 by at least 10%

HOLD (H) - Total return expected to be in-line with S&P 500

SELL (S) - Total return expected to underperform S&P 500 by at least 10%

Distribution of Ratings/IB Services

D. Boral

Rating	Count	Percent	IB Serv./Past 12 Mos.	
			Count	Percent

BUY	42	100.00	15	35.71
HOLD	0	0.00	0	0.00
SELL	0	0.00	0	0.00

NRx Pharmaceuticals, Inc. Rating History as of 11/14/2024

